Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Breast Cancer Research
Published in: Breast Cancer Research 1/2015

Open Access 01-12-2015 | Erratum

Erratum to: “A novel role for ezrin in breast cancer angio/lymphangiogenesis”

Authors: Abdi Ghaffari, Victoria Hoskin, Alvin Szeto, Maaike Hum, Navid Liaghati, Kanji Nakatsu, David LeBrun, Yolanda Madarnas, Sandip SenGupta, Bruce E Elliott

Published in: Breast Cancer Research | Issue 1/2015

Login to get access

Excerpt

Following the publication of our article [1], we noticed that Dr. David LeBrun had inadvertently been omitted from the author list. DL declares he has no conflicts of interest. The author list has now been corrected and the amended authors’ contributions included below. …
Literature
1.
Metadata
Title
Erratum to: “A novel role for ezrin in breast cancer angio/lymphangiogenesis”
Authors
Abdi Ghaffari
Victoria Hoskin
Alvin Szeto
Maaike Hum
Navid Liaghati
Kanji Nakatsu
David LeBrun
Yolanda Madarnas
Sandip SenGupta
Bruce E Elliott
Publication date
01-12-2015
Publisher
BioMed Central
Published in
Breast Cancer Research / Issue 1/2015
Electronic ISSN: 1465-542X
DOI
https://doi.org/10.1186/s13058-014-0511-x

Other articles of this Issue 1/2015

Breast Cancer Research 1/2015 Go to the issue

Erratum

Erratum to: Humanization of the mouse mammary gland by replacement of the luminal layer with genetically engineered preneoplastic human cells

Research article

Upregulation of EGFR signaling is correlated with tumor stroma remodeling and tumor recurrence in FGFR1-driven breast cancer

Review

Molecular mechanism and clinical impact of APOBEC3B-catalyzed mutagenesis in breast cancer

Research article

ALK alteration is a frequent event in aggressive breast cancers

Research article

Lectin RCA-I specifically binds to metastasis-associated cell surface glycans in triple-negative breast cancer

Review

Molecular drivers of lobular carcinoma in situ
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits